


WHAT IS CLAIMED IS:

1. A compound of formula (I)



or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof,
wherein

R^1 and R^2 are each independently hydrogen, halogen, $-C_{1-8}$ alkyl, $-C_{2-8}$ alkenyl, $-C_{2-8}$ alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, $-CN$, $-NO_2$, $-OR^a$, $-SO_2R^a$, $-COR^a$, $-CO_2R^a$, $-CONR^aR^b$, $-C(=NR^a)NR^bR^c$, $-NR^aR^b$, $-NR^aCOR^b$, $-NR^aCONR^bR^c$, $-NR^aCO_2R^b$, $-NR^aSONR^bR^c$, $-NR^aSO_2NR^bR^c$, or $-NR^aSO_2R^b$, each of said $-C_{1-8}$ alkyl, $-C_{2-8}$ alkenyl, $-C_{2-8}$ alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with halogen, hydroxy, $-C_{1-8}$ alkoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R^a , R^b , and R^c are each independently hydrogen, $-C_{1-8}$ alkyl, $-C_{2-8}$ alkenyl, $-C_{2-8}$ alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

n is 0, 1, 2, 3 or 4;

R^3 and R^4 , at each of its occurrence, are independently halogen, $-C_{1-8}$ alkyl, $-C_{2-8}$ alkenyl, $-C_{2-8}$ alkynyl, cycloalkyl, heterocyclyl, $-C_{1-8}$ alkyl-heterocyclyl, $-C_{1-8}$ alkyl-cycloalkyl, aryl, heteroaryl, oxo, $-CN$, $-NO_2$, $-OR^{3a}$, $-SO_2R^{3a}$, $-SO_2NR^{3a}R^{3b}$, $-COR^{3a}$, $-CO_2R^{3a}$, $-CONR^{3a}R^{3b}$, $-C(=NR^{3a})NR^{3b}R^{3c}$, $-NR^{3a}R^{3b}$, $-NR^{3a}COR^{3b}$, $-NR^{3a}CONR^{3b}R^{3c}$, $-NR^{3a}CO_2R^{3b}$, $-NR^{3a}SONR^{3b}R^{3c}$, $-NR^{3a}SO_2NR^{3b}R^{3c}$, or $-NR^{3a}SO_2R^{3b}$, each of said $-C_{1-8}$ alkyl, $-C_{2-8}$ alkenyl, $-C_{2-8}$ alkynyl, cycloalkyl, heterocyclyl, $-C_{1-8}$ alkyl-heterocyclyl, aryl, or heteroaryl is optionally substituted with at least one substituents R^{3d} ; or R^3 and R^4 , when on adjacent carbon atoms of the phenyl ring, together with the two intervening carbon atoms to which they are attached, form a 5- to 8-membered ring comprising 0, 1 or 2 heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member (s), said ring is optionally substituted with at least one substituents R^{3e} ;

or two R^4 , when on adjacent carbon atoms of the phenyl ring, together with the two intervening carbon atoms to which they are attached, form a 5- to 8-membered ring comprising 0, 1 or 2 heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member (s);


R^{3a} , R^{3b} , and R^{3c} are each independently hydrogen, $-C_{1-8}$ alkyl, $-C_{2-8}$ alkenyl, $-C_{2-8}$ alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of said $-C_{1-8}$ alkyl, $-C_{2-8}$ alkenyl, $-C_{2-8}$ alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with at least one substituents R^{3e} ; or

(R^{3a} and R^{3b}), (R^{3b} and R^{3c}), or (R^{3c} and R^{3a}), together with the atom (s) to which they are attached, form a 3- to 12-membered ring, said ring comprising 0, 1 or 2 additional heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member (s), said ring is optionally substituted with at least one substituents R^{3e};

R^{3d} and R^{3e} are each independently halogen, -C₁₋₈alkyl, -C₂₋₈alkenyl, -C₂₋₈alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, -NO₂, -OR^{3f}, -SO₂R^{3f}, -SO₂NR^{3f}R^{3g}, -COR^{3f}, -CO₂R^{3f}, -CONR^{3f}R^{3g}, -C(=NR^{3f})NR^{3g}R^{3h}, -NR^{3f}R^{3g}, -NR^{3f}COR^{3g}, -NR^{3f}CONR^{3g}R^{3h}, -NR^{3f}CO₂R^{3f}, -NR^{3f}SONR^{3f}R^{3g}, -NR^{3f}SO₂NR^{3g}R^{3h}, or -NR^{3f}SO₂R^{3g}, each of said -C₁₋₈alkyl, -C₂₋₈alkenyl, -C₂₋₈alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with at least one substituents selected from halogen, -C₁₋₈alkyl, -OR³ⁱ, -NR³ⁱR^{3j}, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R^{3f}, R^{3g}, R^{3h}, R³ⁱ, and R^{3j} are each independently hydrogen, -C₁₋₈alkyl, C₁₋₈alkoxy-C₁₋₈alkyl-, -C₂₋₈alkenyl, -C₂₋₈alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

L¹ is a single bond, alkylene, cycloalkylene, *¹-O-alkylene-**¹, *¹-alkylene-O-**¹, *¹-NH-alkylene-**¹, *¹-alkylene-NH-**¹, *¹-NHC(O)-**¹, *¹-C(O)NH-**¹, alkenylene, or alkynylene; wherein *¹ refers to the position attached to Cy1, and **¹ refers to the position attached to the pyrrolo[2, 3-b]pyrazine ring;



is a fused heterocyclyl, fused heteroaryl, fused aryl, fused cycloalkyl, fused cycloalkenyl, or fused cycloalkynyl,  is optionally substituted with R⁶;

p is 0, 1, 2, 3, 4;  is optionally substituted with R⁵, m is 0, 1, 2, 3, 4;

R⁵ at each of its occurrence, is each independently halogen, -C₁₋₈alkyl, -C₂₋₈alkenyl, -C₂₋₈alkynyl, cycloalkyl, -C₁₋₈alkyl-cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, -NO₂, -OR^{5a}, -SO₂R^{5a}, -SO₂NR^{5a}R^{5b}, -POR^{5a}R^{5b}, -COR^{5a}, -CO₂R^{5a}, -CONR^{5a}R^{5b}, -C(=NR^{5a})NR^{5b}R^{5c}, -CH₂CONR^{5a}R^{5b}, -CH₂CH₂CONR^{5a}R^{5b}, -CH₂CH₂CH₂CONR^{5a}R^{5b}, -NR^{5a}R^{5b}, -CH₂NR^{5a}R^{5b}, -CH₂CH₂NR^{5a}R^{5b}, -NR^{5a}COR^{5b}, -NR^{5a}CONR^{5b}R^{5c}, -NR^{5a}CO₂R^{5b}, -NR^{5a}SONR^{5b}R^{5c}, -NR^{5a}SO₂NR^{5b}R^{5c}, or -NR^{5a}SO₂R^{5b}, each of said -C₁₋₈alkyl, -C₂₋₈alkenyl, -C₂₋₈alkynyl, cycloalkyl, -C₁₋₈alkyl-cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with at least one substituents R^{5d}; or two R⁵, together with the atoms to which they are attached (provided that the valence theory is met), form a 4-, 5-, 6-, 7- or 8-membered ring, said ring comprising 0, 1 or 2 heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member (s), said ring is optionally substituted with at least one substituents R^{5e};

R^{5a}, R^{5b} and R^{5c} are each independently hydrogen, -C₁₋₈alkyl, -C₂₋₈alkenyl, -C₂₋₈alkynyl, -C₁₋₈alkyl-C₁₋₈alkoxy, cycloalkyl, -C₁₋₈alkyl-heterocyclyl, -C₁₋₈alkyl-aryl, heterocyclyl, aryl, or heteroaryl, each of said -C₁₋₈alkyl, -C₂₋₈alkenyl, -C₂₋₈alkynyl, -C₁₋₈alkyl-C₁₋₈alkoxy, cycloalkyl, -C₁₋₈alkyl-heterocyclyl, -C₁₋₈alkyl-aryl, heterocyclyl, aryl, or heteroaryl is optionally substituted with at least one substituents R^{5e};

(R^{5a} and R^{5b}), (R^{5b} and R^{5c}), or (R^{5c} and R^{5a}), together with the atom (s) to which they are attached, form a 3- to 12-membered ring, said ring comprising 0, 1 or 2 additional heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member (s), said ring is optionally substituted with at least one substituents R^{5e};

R^{5d} and R^{5e} are each independently hydrogen, halogen, -C₁₋₈alkyl, -C₂₋₈alkenyl, -C₂₋₈alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, -NO₂, -CF₃, -OR^{5f}, -SO₂R^{5f}, -SO₂NR^{5f}R^{5g}, -POR^{5f}R^{5g}, -COR^{5f}, -CO₂R^{5f}, -CONR^{5f}R^{5g}, -C(=NR^{5h})NR^{5f}R^{5g}, -NR^{5f}R^{5g}, -NR^{5f}COR^{5g}, -NR^{5h}CONR^{5f}R^{5g}, -NR^{5f}CO₂R^{5h}, -NR^{5h}SONR^{5f}R^{5g}, -NR^{5h}SO₂NR^{5f}R^{5g}, or -NR^{5f}SO₂R^{5g}, each of said -C₁₋₈alkyl, -C₂₋₈alkenyl, -C₂₋₈alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with at least one substituents selected from halogen, -C₁₋₈alkyl, -OR⁵ⁱ, -NR⁵ⁱR^{5j}, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R^{5f}, R^{5g}, R^{5h}, R⁵ⁱ, and R^{5j} are each independently hydrogen, oxo, -C₁₋₈alkyl, -C₁₋₈alkoxy, hydroxy, C₁₋₈alkoxy-C₁₋₈alkyl-, -C₂₋₈alkenyl, -C₂₋₈alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R⁶ at each of its occurrence, is each independently hydrogen, halogen, -C₁₋₈alkyl, -C₂₋₈alkenyl, -C₂₋₈alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, -NO₂, -OR^{6a}, -SO₂R^{6a}, -SO₂NR^{6a}R^{6b}, -COR^{6a}, -CO₂R^{6a}, -CONR^{6a}R^{6b}, -C(=NR^{6a})NR^{6b}R^{6c}, -CH₂CONR^{6a}R^{6b}, -CH₂CH₂CONR^{6a}R^{6b}, -CH₂CH₂CH₂CONR^{6a}R^{6b}, -NR^{6a}R^{6b}, -CH₂NR^{6a}R^{6b}, -CH₂CH₂NR^{6a}R^{6b}, -CH₂CH₂CH₂NR^{6a}R^{6b}, -NR^{6a}COR^{6b}, -NR^{6a}CONR^{6b}R^{6c}, -NR^{6a}CO₂R^{6b}, -NR^{6a}SONR^{6b}R^{6c}, -NR^{6a}SO₂NR^{6b}R^{6c}, or -NR^{6a}SO₂R^{6b}, each of said -C₁₋₈alkyl, -C₂₋₈alkenyl, -C₂₋₈alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with at least one substituents R^{6d}; or two R⁶, together with the atom to which they are attached (provided that the valence theory is met), form a 4-, 5-, 6-, 7- or 8-membered ring, said ring comprising 0, 1 or 2 heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member (s), said ring is optionally substituted with at least one substituents R^{6e};

R^{6a}, R^{6b}, and R^{6c} are each independently hydrogen, -C₁₋₈alkyl, -C₂₋₈alkenyl, -C₂₋₈alkynyl, C₁₋₈alkoxy-C₁₋₈alkyl-, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of said -C₁₋₈alkyl, -C₂₋₈alkenyl, -C₂₋₈alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with at least one substituents R^{6e};

(R^{6a} and R^{6b}), (R^{6b} and R^{6c}), or (R^{6c} and R^{6a}), together with the atom (s) to which they are attached, form a 3- to 12-membered ring, said ring comprising 0, 1 or 2 additional heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member (s), said ring is optionally substituted with at least one substituents R^{6e};


R^{6d} and R^{6e} are each independently hydrogen, halogen, -C₁₋₈alkyl, -C₂₋₈alkenyl, -C₂₋₈alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, -NO₂, -OR^{6f}, -SO₂R^{6f}, -SO₂NR^{6f}R^{6g}, -COR^{6f}, -CO₂R^{6f}, -CONR^{6f}R^{6g}, -C(=NR^{6h})NR^{6f}R^{6g}, -NR^{6f}R^{6g}, -NR^{6f}COR^{6g}, -NR^{6h}CONR^{6f}R^{6g}, -NR^{6f}CO₂R^{6h}, -NR^{6h}SONR^{6f}R^{6g}, -NR^{6h}SO₂NR^{6f}R^{6g}, or -NR^{6f}SO₂R^{6g}, each of said -C₁₋₈alkyl, -C₂₋₈alkenyl, -C₂₋₈alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with at least one substituents selected from halogen, -C₁₋₈alkyl, -OR⁶ⁱ, -NR⁶ⁱR^{6j}, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R^{6f}, R^{6g}, R^{6h}, R⁶ⁱ, and R^{6j} are each independently hydrogen, oxo, -C₁₋₈alkyl, C₁₋₈alkoxy-C₁₋₈alkyl-, -C₂₋₈alkenyl, -C₂₋₈alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl.

2. The compound of claim 1, wherein R¹ and R² are each hydrogen or -C₁-alkyl (preferably hydrogen or methyl).

3. The compound of claim 1 or 2, wherein R³ is -C₁₋₈alkyl, -C₁₋₈alkyl-heterocyclyl or -C₁₋₈alkyl-cycloalkyl, wherein said -C₁₋₈alkyl, -C₁₋₈alkyl-heterocyclyl or -C₁₋₈alkyl-cycloalkyl is optionally substituted with at least one substituents R^{3d}; R^{3d} is independently selected from -C₁₋


galkyl or -OR^{3f}; R^{3f} is each independently hydrogen, -C₁₋₈alkyl; preferably R³ is




4. The compound of claim 1 or 2, wherein R³ is -CONR^{3a}R^{3b}; R^{3a} and R^{3b} are each independently hydrogen or -C₁₋₈alkyl (preferably methyl, ethyl, propyl, butyl, pentyl or hexyl); each of said -C₁₋₈alkyl is substituted with at least one substituents selected from hydrogen, -OR^{3f}, CN, 3- to-7 membered heterocyclyl comprising 1 or 2 heteroatoms selected from nitrogen, oxygen (for example, piperazinyl, piperidiny, piperidiny, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyranyl, or pyrrolidinyl); R^{3f} is selected from hydrogen or -C₁₋₈alkyl (e.g., methyl, ethyl, propyl, butyl, pentyl or hexyl).

5. The compound of claim 1 or 2, wherein R³ is -CONR^{3a}R^{3b} or -NR^{3a}R^{3b}; R^{3a} and R^{3b} together with the nitrogen atom to which they are attached is 4- to 12-membered ring comprising 1 or 2 additional nitrogen or oxygen heteroatoms as ring member (e.g., monocyclic 3- to 8-membered ring or bicyclic spiro 7- to 12-membered ring), said ring is optionally substituted with at least one substituents R^{3e}; R^{3e} each is selected from oxo, -C₁₋₈alkyl, -OR^{3f}, -NR^{3f}R^{3g}, said-C₁₋₈alkyl is optionally substituted by at least one halogen, wherein R^{3f} and R^{3g} are each independently hydrogen, or -C₁₋₈alkyl.

6. The compound of any claims 1-5, wherein R³ is selected from














7. The compound of any claims 1-5, wherein R^3 is selected from  or .








8. The compound of any claims 1-7, wherein n is 0, 1 or 2; R^4 is selected from halogen, $-C_{1-8}$ alkyl (preferably methyl), halogen, CN, $-OR^{3a}$ or $-NR^{3a}CONR^{3b}R^{3c}$; said $-C_{1-8}$ alkyl is optionally substituted with at least one substituents R^{3d} ; R^{3a} , R^{3b} and R^{3c} are each independently hydrogen, $-C_{1-8}$ alkyl (preferably methyl); R^{3d} is each independently halogen or $-C_{1-8}$ alkyl.


9. The compound of claim 8, wherein n is 1, R^4 is selected from $-C_{1-8}$ alkyl (preferably methyl), halogen, CN, OR^{3a} or $-NR^{3a}CONR^{3b}R^{3c}$; said $-C_{1-8}$ alkyl is optionally substituted with at least one substituents R^{3d} ; R^{3a} , R^{3b} and R^{3c} are each independently hydrogen, or $-C_{1-8}$ alkyl (preferably methyl); R^{3d} is each independently halogen or $-C_{1-8}$ alkyl.

10. The compound of claim 8, wherein n is 2, and R^4 is halogen.


11. The compound of claim 8, wherein n is 1 or 2, and R^4 is selected from methyl, F, OH, CN, $-CHF_2$ or $-NHCOCH_3$.

12. The compound of any claims 1-8, wherein n is 0, and R^3 is selected from , , , , , , , , , or  or .

13. The compound of any claims 1-9, 11, wherein n is 1, and R^3 is selected from , , , , , , or ; and R^4 is methyl, F, OH, CN, $-CHF_2$ or $-NHCOCH_3$.


14. The compound of any claims 1-8, 10-11, wherein n is 2, and R^3 is selected from , and R^4 is F.

15. The compound of any claims 1-2, wherein R^3 and R^4 , when on adjacent carbon atoms of the phenyl ring, together with the two intervening carbon atoms to which they are attached, form a 5- to 8-membered ring comprising 0, 1 or 2 heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member (s), said ring is optionally substituted with at least one substituents R^{3e} ; each R^{3e} is independently selected from $-C_{1-8}$ alkyl or oxo.




16. The compound of claim 15, wherein is $X=NH$ or O , and R^{3e} is $-C_{1-8}alkyl$.

17. The compound of any claims 1-2, wherein $n=2$, two R^4 when on adjacent carbon atoms of the phenyl ring, together with the two intervening carbon atoms to which they are attached, form a 5- to 8-membered ring comprising 0, 1 or 2 heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member (s).




18. The compound of claim 17, wherein is ; and two R^4 , when on adjacent carbon atoms of the phenyl ring, together with the two intervening carbon atoms to which they are attached, form a 5-membered ring comprising 2 heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur as ring member (s).



19. The compound of claim 18, wherein is or .

20. The compound of any claims 1-19, L^1 is a single bond.



21. The compound of any claims 1-20, wherein is benzo fused heterocyclyl, benzo fused heteroaryl, benzo fused cycloalkyl, benzo fused cycloalkenyl, benzo fused cycloalkynyl.


22. The compound of claim 21, wherein the benzo fused heterocyclyl is indolinyl, isoindolinyl, benzopyranyl, dihydrothiazolopyrimidinyl, tetrahydroquinolyl, tetrahydroisoquinolyl, dihydrobenzofuranyl, dihydrobenzoxazinyl, dihydrobenzoimidazolyl, tetrahydrobenzothienyl, tetrahydrobenzofuranyl, benzodioxolyl, benzodioxonyl, chromanyl, chromenyl, octahydrochromenyl, dihydrobenzodioxynyl, dihydrobenzoxezynyl, dihydrobenzodioxepinyl, dihydrothienodioxynyl, dihydrobenzooxazepinyl, tetrahydrobenzooxazepinyl, dihydrobenzoazepinyl, tetrahydrobenzoazepinyl, isochromanyl, or chromanyl.


23. The compound of claim 21 or 22, wherein the benzo fused heterocyclyl is indolinyl, isoindolinyl, tetrahydroisoquinolyl, dihydrobenzofuranyl, dihydrobenzoimidazolyl, tetrahydrobenzooxazepinyl, tetrahydrobenzoazepinyl, or isochromanyl.


24. The compound of claim 23, wherein tetrahydroisoquinolyl is selected from 1, 2, 3, 4-tetrahydroisoquinolyl, 1, 2, 3, 4-tetrahydroisoquinolin-6-yl or 1, 2, 3, 4-tetrahydroisoquinolin-7-yl; tetrahydrobenzooxazepinyl is selected from 2, 3, 4, 5-tetrahydrobenzooxazepinyl, 2, 3, 4, 5-tetrahydrobenzo[f][1, 4]oxazepin-8-yl, or 2, 3, 4, 5-tetrahydrobenzo[f][1, 4]oxazepin-7-yl;




tetrahydrobenzoazepinyl is selected from 2, 3, 4, 5-tetrahydrobenzoazepinyl, 2, 3, 4, 5-tetrahydro-1H-benzo[c]azepin-7-yl and 2, 3, 4, 5-tetrahydro-1H-benzo[d]azepin-7-yl; isoindolinyl is selected from isoindolin-5-yl; isochromanyl is selected from isochroman-5-yl; dihydroisobenzofuranyl is selected from 1, 3-dihydroisobenzofuran-4-yl.






25. The compound of claim 21, wherein the benzo fused heteroaryl is benzisoxazolyl, benzodiazolyl, benzofuranyl, benzofurazanyl, benzofuryl, benzoimidazolyl, benzoisothiazolyl, benzothiadiazolyl, benzothiazolyl, benzothienyl, benzothiophenyl, benzotriazolyl, benzoxadiazolyl, benzoxazolyl, indazolyl, indolyl, isobenzofuryl, isoindolyl, isoquinolinyl (or isoquinolyl), phthalazinyl, pteridiny, purinyl, quinazolinyl, quinolinyl (or quinolyl), or quinoxalinyl; in some examples, indazolyl is e.g., 1H-indazol-4-yl, 2H-indazol-4-yl, 1H-indazol-5-yl, 2H-indazol-5-yl, 1H-indazol-7-yl; benzodiazolyl is e.g., 1H-benzo[d]imidazol-4-yl, 1H-1, 3-benzodiazol-5-yl or 1H-benzo[d]imidazol-5-yl, 1H-benzo[d]imidazol-4-yl, 1H-benzo[d]imidazol-6-yl; benzooxazolyl is e.g., benzo[d]oxazol-6-yl; benzooxadiazolyl is e.g., benzo[c][1, 2, 5]oxadiazol-4-yl.



26. The compound of claim 21, wherein  is a bicyclic fused heteroaryl selected from furopyridinyl, furopyrrolyl, imidazopyridinyl, imidazopyridyl, imidazothiazolyl, indoliziny, naphthyridinyl, pyrazinopyridazinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, pyrazolopyridyl, pyrazolotriazinyl, pyridazolopyridyl, pyrrolopyridinyl, thiazolopyridyl, thienopyrazinyl, thienopyrazolyl, thienopyridyl, thienopyrrolyl, thienothienyl, or triazolopyridyl; in some example, imidazopyridinyl is e.g., imidazo[1, 2-a]pyridin-5-yl or imidazo[1, 5-a]pyridin-5-yl.




27. The compound of claim 21, wherein  is  or , $p=0, 1, 2$ or 3 ; $m=0, 1, 2, 3$ or 4 ; R^6 and R^5 are defined for Formula (I).

28. The compound of any claims 21-27, wherein  is  or  (preferably  or , $m=1, 2, 3$ or 4 ; R^6 and R^5 are defined for Formula (I) (preferably R^5 and R^6 are independently $-C_{1-8}$ alkyl (e.g., methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-methyl-1-propyl, 1-methylpropyl or t-butyl).

29. The compound of any claims 27-28, wherein R^6 is selected from $-C_{1-8}$ alkyl, $-OR^{6a}$ or $-NR^{6a}R^{6b}$, said $-C_{1-8}$ alkyl is optionally substituted with at least one substituents R^{6d} , R^{6a} and R^{6b}

30. The compound of any claims 27-29, wherein each R⁵ is independently selected from -C₁₋₈alkyl, -C₁₋₈alkyl-cycloalkyl, heterocyclyl or heteroaryl -CONR^{3a}R^{3b}, CH₂CONR^{5a}R^{5b}, -CH₂CH₂CONR^{5a}R^{5b}, -NR^{5a}R^{5b}, -CH₂NR^{5a}R^{5b}, -CH₂CH₂NR^{5a}R^{5b}, said -C₁₋₈alkyl, -C₁₋₈alkyl-cycloalkyl or heterocyclyl or heteroaryl is optionally substituted with at least one R^{5d}, and R^{5a}, R^{5b} and R^{5d} are defined for Formula (I).

32. The compound of claim 31, wherein, R⁵ is methyl, ethyl, propyl, butyl, pentyl or hexyl,



34. The compound of claim 33, wherein R⁵ is








132

36. The compound of claim 35, wherein R⁵ is selected from -CONR^{5a}R^{5b}, -CH₂CONR^{5a}R^{5b}, -CH₂CH₂CONR^{5a}R^{5b}, wherein R^{5a} is hydrogen or -C₁₋₈alkyl (e.g., methyl, ethyl); R^{5b} is selected from -C₁₋₈alkyl, cycloalkyl, -C₁₋₈alkyl-heterocyclyl, -C₁₋₈alkyl-aryl, heterocyclyl, aryl, said -C₁₋₈alkyl, cycloalkyl, -C₁₋₈alkyl-heterocyclyl, -C₁₋₈alkyl-aryl, heterocyclyl, aryl is optionally substituted with at least one substituents R^{5c}, R^{5c} is selected from halogen, -CH₂OH or OR^{5f}, R^{5f} is selected from hydrogen, cycloalkyl or -C₁₋₈alkyl.


37. The compound of claim 36, wherein R⁵ is selected from




38. The compound of claim 35 or 36, wherein R⁵ is -CONR^{3a}R^{3b}, CH₂CONR^{5a}R^{5b} or -CH₂CH₂CONR^{5a}R^{5b}, R^{5a} is hydrogen or methyl; and R^{5b} is selected from cycloalkyl, such as cycloalkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, and cyclododecyl groups; said cycloalkyl is





39. The compound of claim 35 or 36, wherein R⁵ is -CONR^{5a}R^{5b}, CH₂CONR^{5a}R^{5b} or -CH₂CH₂CONR^{5a}R^{5b}, R^{5a} is hydrogen or methyl; and R^{5b} is selected from -C₁₋₈alkyl, cycloalkyl or -C₁₋₈alkyl-heterocyclyl, said -C₁₋₈alkyl, cycloalkyl or -C₁₋₈alkyl-heterocyclyl is optionally substituted with at least one substituents R^{5c}, R^{5c} is selected from cycloalkyl, -C₁₋₈alkyl, -CH₂OH or OR^{5f}, OR^{5f} is selected from hydrogen or -C₁₋₈alkyl. For example, R⁵ is selected from






43. The compound of claim 28, wherein
















































$m=2$, R^5 is each independently $-C_{1-8}$ alkyl or $-\text{CONR}^{5a}\text{R}^{5b}$, R^{5b} and R^{5d} are hydrogen or $-C_{1-8}$ alkyl (e.g., methyl, ethyl, propyl, butyl, pentyl or hexyl); R^6 is selected from $-C_{1-8}$ alkyl, $-\text{OR}^{6a}$ or $-\text{NR}^{6a}\text{R}^{6b}$, said $-C_{1-8}$ alkyl is optionally substituted with at least one substituents R^{6d} , R^{6a} and R^{6b} are each hydrogen or $-C_{1-8}$ alkyl; R^{6d} is each independently hydrogen, halogen or $-C_{1-8}$ alkyl; preferably R^6 is selected from $-\text{CH}_3$, $-\text{OCH}_3$, $-\text{NHCH}_3$, $-\text{CHF}_2$, or $-\text{C}(\text{CH}_3)_2\text{OH}$.
























R^6 is selected from $-\text{CH}_3$, $-\text{OCH}_3$, $-\text{NHCH}_3$, $-\text{CHF}_2$, or $-\text{C}(\text{CH}_3)_2\text{OH}$.

46. The compound of claim 1, selected from:






















		
1	2	3
		
4	5	6
		
7A	7B	8
		
9	10	11
		
12	13	14
		
15	16	17
		
18	19	20

		
21	22	23
		
24	25	26
		
27	28	29
		
30	31	32
		
33	34	35
		
36	37	38
		
39	40	41
		
42	43	44

		
45	46	47
		
48	49	50
		
51	52	53
		
54	55	56
		
57	58	59
		
60	61	62
		
63	64	65

66	67	68
69	70	71
72	73	74
75	76	77
78	79	80
81	82	83

84	85	86
87	88	89
90	91	92
93	94	95
96	97	98
99	100	101
102	103	104
105	106	107

		
108	109	110
		
111	112	113
		
114	115	116
		
117	118	119
		
120	121	122
		
123	124	125
		
126	127	128

47. A pharmaceutical composition comprising the compound of any of claims 1-46 or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

48. A method of treating cancer, comprising administering a subject in need thereof the compound of any of claims 1-46 or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.